Woodruff Lab - Services - School of Biomedical Sciences

We specialise in Parkinson’s disease, motor neuron disease; MND (amyotrophic lateral sclerosis; ALS) and neuroinflammation assays.

Capacity in preclinical drug testing (efficacy) indisease models, or target validation studies.
Range of state-of-the-art disease models accepted by funders and regulators as best-practice preclinical efficacy models.
An extensive range of both standardised and novelbehavioural and pathological analyses that can becustomised to suit individual requirements.
Can be coupled with pharmacodynamic and pharmacokinetic data from the same animal to maximisedata output and assay validation.
Successful record in completing industry contracts,with two drugs undergoing human clinical trialsafter successful testing in preclinical models.
Strong publication track record in preclinical neurodegenerative disease animal studies.
Offer opportunities for leverage funding throughnon-diluting grant funding.
Competitive rates for both fee-for-service or collaborative research projects.

In vivo models available

In vitro/ex vivo models available

Neurotransmitter/Neurochemical Quantitation

We offer new methods to simultaneously measure a range of neurotransmitters and metabolites from any sample.
We utilise state-of-the-art LC-MS/MS methodology to provide full quantitation of analytes coupled with standard curves.
We have the ability to determine concentrations in a wide range of biological fluids or tissues from any animal or human species.
Analyses can be easily coupled with efficacy studies in neurodegenerative disease or psychiatry models to allow fullquantitation of drug activities.

Currently available as fully-quantitated neurotransmitters:

Also currently available as fully-quantitated short-chain fatty acids and metabolites